ライフサイエンスコーパス: debulk

1 tment interventions (predominantly localised debulking).

2 initive tissue diagnosis, staging, and tumor debulking.

3 ard chemotherapy, immunotherapy, or surgical debulking.

4 s underwent stent implantation without prior debulking.

5 ersist clinically after laparotomy and tumor debulking.

6 acryoadenitis who were managed with surgical debulking.

7 -type HGSOC) who underwent CT before primary debulking.

8 and in preventing recurrences after surgical debulking.

9 owth of metastatic tumor foci after surgical debulking.

10 ary resection methods for utilizing FGS: (1) debulking, (2) wide local excision, and (3) whole organ

11 edian survival time for women with optimally debulked adenocarcinoma of the ovary treated with intrav

12 y univariate analysis included partial mucin debulking, adenocarcinoma histology, systemic chemothera

13 ays after tumor inoculation) were surgically debulked and animals were treated with rofecoxib startin

14 OvCa patients initially respond to surgical debulking and chemotherapy, 75% of patients later succum

15 istically with radiotherapy to improve tumor debulking and control in preclinical models.

16 h NSCLC were enrolled; 17 underwent complete debulking and PDT, three underwent partial debulking/PDT

17 ents with a complete clinical response after debulking and platinum-based chemotherapy: the five-year

18 with metastasis, advanced stage, suboptimal debulking and poor prognosis.

19 ministered enabled acute autochthonous tumor debulking and resulted in durable clinical remission.

20 y was to limit instrumentation to extraction debulking and to stabilizing the site with stent deploym

21 Debulking and trimming effectively managed all cases of

22 es with mucosal overgrowth underwent mucosal debulking and trimming.

23 f treatment with ASHAP is an effective tumor debulking approach in patients previously treated with b

24 or adequate staging of nodal status or tumor debulking before secondary therapy.

25 most patients with SVG aortoostial lesions, debulking before stent implantation may not be necessary

26 However, the impact of debulking before stenting in this complex lesion subset

27 Debulking biopsy procedures for idiopathic dacryoadeniti

28 esion, 44 patients with 50 lesions underwent debulking by laser angioplasty, rotational or directiona

29 ted for Y-redirected cells and enabled tumor debulking by tumor-redirected lymphocytes.

30 While this therapy is effective at rapidly debulking directly injected tumor masses, achieving comp

31 A chemotherapy strategy was used to debulk disease before administration of granulocyte colo

32 will address the same question in optimally debulked disease.

33 us (IV) chemotherapy in women with optimally debulked epithelial ovarian cancer confined to the abdom

34 was evaluated in 139 advanced, suboptimally debulked epithelial ovarian cancer specimens from patien

35 uspected advanced ovarian cancer is surgical debulking followed by platinum-based chemotherapy.

36 ear clinical outcomes in patients undergoing debulking followed by stent implantation versus stenting

37 The benefits of debulking for bifurcation lesions were especially seen i

38 ess was 73% in the PTCA group and 97% in the debulking group (p = 0.01).

39 n the PTCA group as compared with 28% in the debulking group (p = 0.05).

40 wo patients in the PTCA group and one in the debulking group.

41 esions) underwent stent implantation without debulking (group II).

42 uited from non-UK centers who were similarly debulked (hazard ratio = 1.85; 95% CI, 1.16 to 2.97; P =

43 ng for case selection rather than aggressive debulking in all patients irrespective of disease extent

44 a randomised trial that supported aggressive debulking in patients with MSCC.

45 oaches (perhaps in conjunction with surgical debulking) in human clinical trials of treatment of meso

46 nsists of surgical staging, operative tumour debulking including total abdominal hysterectomy and bil

47 iac tumors indicates that a less risky tumor debulking is effective for a subset of histotypes such a

48 ction of patients with a history of previous debulking), lack of invasive tumor growth, and minimal r

49 tients, who were more likely to be optimally debulked (< or = 2 cm residual disease) than UK patients

50 Surgical debulking may have a role in symptom control beyond that

51 Further, issues regarding the role of debulking nephrectomy, timing of therapy, and appropriat

52 m in diameter; (2) pneumatic dissection; (3) debulking of approximately 80% of the anterior stroma; (

53 , the potential for atraumatic and effective debulking of atheromatous plaque through a biological me

54 The monolithic CTC-iChip enables debulking of blood samples at 15-20 million cells per se

55 Seven patients had palliative debulking of cervical tumor.

56 ause it provides the most effective clinical debulking of hematologic malignancies, and because CSC-t

57 aging, we first showed quantitative surgical debulking of human GBM tumors in mice, which resulted in

58 tion of tumor cells remaining after surgical debulking of malignant brain tumors.

59 hermore, the model can suggest whether prior debulking of the tumor with chemo-immunotherapy can prol

60 ed the effect of plaque burden modification (debulking) on the short- and long-term clinical outcomes

61 nce of optimal debulking with regard to PFS (debulking optimal v suboptimal: HR, 0.51; 95% CI, 0.30 t

62 vor of cisplatin for patients with optimally debulked ovarian and limited-stage small-cell lung cance

63 latin were equally effective in suboptimally debulked ovarian cancer and extensive-stage small-cell l

64 en in 62 (45%) of the advanced, suboptimally debulked ovarian cancer patients.

65 in in chemotherapy regimens for suboptimally debulked ovarian cancer.

66 constitute a standard therapy for optimally debulked ovarian cancer.

67 e of IP chemotherapy in women with optimally debulked ovarian cancer.

68 2-year survival rate in women with optimally debulked ovarian cancer.

69 suboptimally (P = 0.0179) but not optimally debulked (P = 0.144) patients.

70 nificantly reduced the recurrence rate after debulking (P < 0.01).

71 For suboptimally debulked patients, confirmation of the predictive gene s

72 to therapeutic intervention in suboptimally debulked patients, pathway analysis was completed for th

73 have beneficial effects on PFS in optimally debulked patients.

74 Splenectomy may reverse AMR by debulking PCs.

75 e debulking and PDT, three underwent partial debulking/PDT, and two patients were unresectable.

76 ces for crossing chronic total occlusions or debulking plaque with atherectomy are less rigorously st

77 larization rates were the same (16.3% in the debulking plus stent group vs. 14.4% in the stent alone

78 e the entire treatment arc including pre-HCT debulking, possibly with hypomethylating agents, conditi

79 ly, the presence of ALDH(+)CD133(+) cells in debulked primary tumor specimens correlated with reduced

80 sions in the group of patients who underwent debulking prior to stenting.

81 ore was 90 (range, 70 to 100), and 77% had a debulking procedure.

82 herapy have prolonged overall survival after debulking procedures.

83 s; however, none required further surgery to debulk radiation necrosis.

84 Treatment regimens include debulking, radiotherapy with IP radioisotopes, and chemo

85 oyment with and without lesion modification (debulking) results in a favorable in-hospital outcome, w

86 Cosmetic blepharoplasty with fat pad debulking should be performed at least 6 months prior to

87 of this approach in patients with optimally debulked stage III ovarian cancer.

88 improves survival in patients with optimally debulked stage III ovarian cancer.

89 n, and IV paclitaxel in women with optimally debulked, stage III ovarian cancer.

90 ontrolling for clinical parameters including debulking status and age (multivariate analysis p = 0.00

91 iables such as age, stage, grade, histology, debulking status and response to chemotherapy continue t

92 Preoperative CA-125 level, debulking status, and ascites were also significant surv

93 at surgery, preoperative serum CA-125 level, debulking status, and ascites, moderate-to-large pleural

94 When adjusted for age, stage, and debulking status, the score predicted progression-free s

95 ostic factors such as age, stage, grade, and debulking status.

96 ostic factors such as age, stage, grade, and debulking status.

97 ll resected tumors were derived from routine debulking surgeries.

98 ajor postoperative complications (P < .001), debulking surgery (CCR 2 or 3; P < .001), prior chemothe

99 8), high peritoneal cancer index (P = .013), debulking surgery (completeness of cytoreduction [CCR],

100 a malignancy before undergoing primary HGSC debulking surgery (n = 14) or patients at disease recurr

101 ric disease, outcomes are comparable between debulking surgery alone, immunochemotherapy alone, or a

102 -FES PET was in accordance with histology at debulking surgery but not at primary diagnosis, indicati

103 d toxicity and by the low 2.5% prevalence of debulking surgery for symptomatic radiation necrosis.

104 The role of debulking surgery in human immunodeficiency virus (-) MC

105 At referral, all patients underwent debulking surgery of the inflammatory lacrimal gland mas

106 he likelihood of complete resection although debulking surgery often is believed to be useful in pati

107 nced ovarian cancer, patients should undergo debulking surgery or chemotherapy to achieve a minimal d

108 aring large tumors with 5 mg/kg/d SM16 after debulking surgery reduced the extent of tumor recurrence

109 epithelial ovarian cancer who had undergone debulking surgery to receive one of three treatments.

110 elial ovarian cancer were treated (following debulking surgery) with paclitaxel as a 3-hour infusion

111 At 2 months after the debulking surgery, a full clinical recovery was seen in

112 nal hazards model were a history of previous debulking surgery, absence of deep tissue invasion, mini

113 tology available at primary diagnosis and at debulking surgery, immunohistochemical ERalpha expressio

114 ids persisting in the peritoneal fluid after debulking surgery.

115 d with neoadjuvant chemotherapy and interval debulking surgery.

116 A resective or debulking surgical approach was described in 77.0% of al

117 rian cancer patients who have been optimally debulked survive longer.

118 Nevertheless, utilization of stenting and debulking techniques improves immediate and long-term ou

119 Debulking techniques may allow the optimal deployment of

120 aditionally, surgical treatment consisted of debulking that was repeated until no further benefit cou

121 , 2009, after a surgical procedure aiming to debulk the disease, women with International Federation

122 n activated thiopropyl resin was employed to debulk the tissue extract by selectively removing a subs

123 ntervention with the intent to cure (90%) or debulk the tumor (9%).

124 mer-docetaxel conjugate (P-DTX) effective in debulking the tumor mass.

125 could be used to allow microscopic surgical debulking to assure maximal surgical effort.

126 e experience has shown that optimum surgical debulking to leave residual tumour deposits that are les

127 with survival in optimally and suboptimally debulked tumor sets at a P value of <0.01.

128 d symptomatic treatment is based on surgical debulking, tumor embolization, and biotherapy with somat

129 ognostic classifier defined for suboptimally debulked tumors may aid in the classification and enhanc

130 sion profiles of advanced stage suboptimally debulked tumors.

131 ining VS-5584 with classic chemotherapy that debulks tumors may engender a more effective strategy to

132 Cytotoxic chemotherapy is effective in debulking tumour masses initially; however, in some pati

133 ediate angiographic and long-term results of debulking versus balloon angioplasty for treatment of tr

134 Aggressive surgical debulking, very close observation of the course of disea

135 Second, optimal debulking was associated with increased PFS mainly for p

136 Recurrence of the tumor after debulking was monitored.

137 fluorescence surgery for tumor debulking, wide local excision, whole-organ resection, a

138 Debulking with excimer laser or atherectomy was performe

139 Plaque debulking with lasing before PTCA may result in improved

140 Tissue debulking with RA yielded better results only in diabeti

141 analyses confirmed the importance of optimal debulking with regard to PFS (debulking optimal v subopt

142 e branch) with conventional PTCA (n = 30) or debulking (with rotational or directional atherectomy) p